235 related articles for article (PubMed ID: 20943046)
1. The role of etanercept on the expression of markers of T helper 17 cells and their precursors in skin lesions of patients with psoriasis vulgaris.
Antiga E; Volpi W; Chiarini C; Cardilicchia E; Filì L; Manuelli C; Parrochi P; Fabbri P; Caproni M
Int J Immunopathol Pharmacol; 2010; 23(3):767-74. PubMed ID: 20943046
[TBL] [Abstract][Full Text] [Related]
2. Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris.
Antiga E; Volpi W; Cardilicchia E; Maggi L; Filì L; Manuelli C; Parronchi P; Fabbri P; Caproni M
J Clin Immunol; 2012 Dec; 32(6):1221-32. PubMed ID: 22699761
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.
Lee JH; Youn JI; Kim TY; Choi JH; Park CJ; Choe YB; Song HJ; Kim NI; Kim KJ; Lee JH; Yoo HJ
BMC Dermatol; 2016 Jul; 16(1):11. PubMed ID: 27455955
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial.
Caproni M; Antiga E; Melani L; Volpi W; Del Bianco E; Fabbri P
J Clin Immunol; 2009 Mar; 29(2):210-4. PubMed ID: 18763027
[TBL] [Abstract][Full Text] [Related]
5. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
Gisondi P; Del Giglio M; Cotena C; Girolomoni G
Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
[TBL] [Abstract][Full Text] [Related]
6. Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment.
de Groot M; Teunissen MB; Picavet DI; de Rie MA; Bos JD
Exp Dermatol; 2010 Aug; 19(8):754-6. PubMed ID: 20482616
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.
Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Giuliano A; Sabato S; Stramazzotti D; Gulini E; Dusi D; De Blasio S; Fabris G; Offidani A
Int J Immunopathol Pharmacol; 2009; 22(2):371-7. PubMed ID: 19505391
[TBL] [Abstract][Full Text] [Related]
8. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC.
Maggi L; Santarlasci V; Capone M; Peired A; Frosali F; Crome SQ; Querci V; Fambrini M; Liotta F; Levings MK; Maggi E; Cosmi L; Romagnani S; Annunziato F
Eur J Immunol; 2010 Aug; 40(8):2174-81. PubMed ID: 20486123
[TBL] [Abstract][Full Text] [Related]
9. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober BE; Clarke S
J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
[TBL] [Abstract][Full Text] [Related]
10. Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study Group.
Cassano N; Loconsole F; Miracapillo A; Travaglini M; Digiuseppe MD; Congedo M; Galluccio A; Buquicchio R; Mastrandrea V; Filieri M; Raho G; Pezza M; Vena GA
Int J Immunopathol Pharmacol; 2010; 23(3):797-802. PubMed ID: 20943050
[TBL] [Abstract][Full Text] [Related]
11. Acitretin exerted a greater influence on T-helper (Th)1 and Th17 than on Th2 cells in treatment of psoriasis vulgaris.
Niu X; Cao W; Ma H; Feng J; Li X; Zhang X
J Dermatol; 2012 Nov; 39(11):916-21. PubMed ID: 22913391
[TBL] [Abstract][Full Text] [Related]
12. Palmoplantar pustulosis with arthro-osteitis: successful treatment with etanercept and acitretin.
Antoniou C; Nicolaidou E; Moustou AE; Stratigos A; Katsambas A
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):854-5. PubMed ID: 19646137
[No Abstract] [Full Text] [Related]
13. [Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept].
Mahiques L; Pitarch G; Sánchez-Carazo JL; Pérez-Ferriols A; Soriano CJ; Alegre V
Actas Dermosifiliogr; 2007 Oct; 98(8):539-44. PubMed ID: 17919428
[TBL] [Abstract][Full Text] [Related]
14. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
15. Increased plasmacytoid dendritic cells and RORγt-expressing immune effectors in cutaneous acute graft-versus-host disease.
Malard F; Bossard C; Brissot E; Chevallier P; Guillaume T; Delaunay J; Mosnier JF; Moreau P; Grégoire M; Gaugler B; Mohty M
J Leukoc Biol; 2013 Dec; 94(6):1337-43. PubMed ID: 23990625
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N
J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
[TBL] [Abstract][Full Text] [Related]
19. Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies.
van Lingen RG; Körver JE; van de Kerkhof PC; Berends MA; van Rens DW; Langewouters AM; Boezeman JB; Seyger MM; de Jong EM
Br J Dermatol; 2008 Jul; 159(1):91-6. PubMed ID: 18476954
[TBL] [Abstract][Full Text] [Related]
20. Brief report: etanercept inhibits the tumor necrosis factor α-driven shift of Th17 lymphocytes toward a nonclassic Th1 phenotype in juvenile idiopathic arthritis.
Maggi L; Cimaz R; Capone M; Santarlasci V; Querci V; Simonini G; Nencini F; Liotta F; Romagnani S; Maggi E; Annunziato F; Cosmi L
Arthritis Rheumatol; 2014 May; 66(5):1372-7. PubMed ID: 24470328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
